| PD-L1 expression in triple-negative breast cancer EA Mittendorf, AV Philips, F Meric-Bernstam, N Qiao, Y Wu, S Harrington, ... Cancer immunology research 2 (4), 361-370, 2014 | 1304 | 2014 |
| PD-L1 expression in triple-negative breast cancer. Cancer Immunol. Res. 2014; 2: 361–370. doi: 10.1158/2326-6066 EA Mittendorf, AV Philips, F Meric-Bernstam, N Qiao, Y Wu, S Harrington, ... CIR-13-0127.[Europe PMC free article][Abstract][CrossRef][Google Scholar], 0 | 240 | |
| PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors F Meric-Bernstam, A Akcakanat, H Chen, KA Do, T Sangai, F Adkins, ... Clinical cancer research 18 (6), 1777-1789, 2012 | 230 | 2012 |
| Targeting the PI3-kinase/Akt/mTOR signaling pathway B Hassan, A Akcakanat, AM Holder, F Meric-Bernstam Surgical Oncology Clinics 22 (4), 641-664, 2013 | 222 | 2013 |
| Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation Y Xing, NU Lin, MA Maurer, H Chen, A Mahvash, A Sahin, A Akcakanat, ... Breast Cancer Research 21, 1-12, 2019 | 193 | 2019 |
| Biomarkers of response to Akt inhibitor MK-2206 in breast cancer T Sangai, A Akcakanat, H Chen, E Tarco, Y Wu, KA Do, TW Miller, ... Clinical Cancer Research 18 (20), 5816-5828, 2012 | 177 | 2012 |
| Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors A Moreno, A Akcakanat, MF Munsell, A Soni, JC Yao, F Meric-Bernstam Endocrine-Related Cancer 15 (1), 257-266, 2008 | 156 | 2008 |
| eIF4E knockdown decreases breast cancer cell growth without activating Akt signaling A Soni, A Akcakanat, G Singh, D Luyimbazi, Y Zheng, D Kim, ... Molecular cancer therapeutics 7 (7), 1782-1788, 2008 | 131 | 2008 |
| High stearoyl-CoA desaturase 1 expression is associated with shorter survival in breast cancer patients AM Holder, AM Gonzalez-Angulo, H Chen, A Akcakanat, KA Do, ... Breast cancer research and treatment 137, 319-327, 2013 | 122 | 2013 |
| Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in … AM Gonzalez-Angulo, A Akcakanat, S Liu, MC Green, JL Murray, H Chen, ... Annals of oncology 25 (6), 1122-1127, 2014 | 103 | 2014 |
| Weekly nab-Rapamycin in patients with advanced nonhematologic malignancies: final results of a phase I trial AM Gonzalez-Angulo, F Meric-Bernstam, S Chawla, G Falchook, D Hong, ... Clinical Cancer Research 19 (19), 5474-5484, 2013 | 89 | 2013 |
| Rapamycin regulates stearoyl CoA desaturase 1 expression in breast cancer D Luyimbazi, A Akcakanat, PF McAuliffe, L Zhang, G Singh, ... Molecular cancer therapeutics 9 (10), 2770-2784, 2010 | 84 | 2010 |
| Aberrations in translational regulation are associated with poor prognosis in hormone receptor-positive breast cancer F Meric-Bernstam, H Chen, A Akcakanat, KA Do, A Lluch, BT Hennessy, ... Breast Cancer Research 14, 1-11, 2012 | 83 | 2012 |
| Aberrations in translational regulation are associated with poor prognosis in hormone receptor-positive breast cancer F Meric-Bernstam, H Chen, A Akcakanat, KA Do, A Lluch, BT Hennessy, ... Breast Cancer Research 14, 1-11, 2012 | 83 | 2012 |
| Oxidative phosphorylation is a metabolic vulnerability in chemotherapy-resistant triple-negative breast cancer KW Evans, E Yuca, SS Scott, M Zhao, N Paez Arango, CX Cruz Pico, ... Cancer research 81 (21), 5572-5581, 2021 | 82 | 2021 |
| Colocalized delivery of rapamycin and paclitaxel to tumors enhances synergistic targeting of the PI3K/Akt/mTOR pathway E Blanco, T Sangai, S Wu, A Hsiao, GU Ruiz-Esparza, ... Molecular therapy 22 (7), 1310-1319, 2014 | 80 | 2014 |
| Comparison of Akt/mTOR signaling in primary breast tumors and matched distant metastases A Akcakanat, A Sahin, AN Shaye, MA Velasco, F Meric‐Bernstam Cancer: Interdisciplinary International Journal of the American Cancer …, 2008 | 73 | 2008 |
| Heterogeneous expression of GAGE, NY‐ESO‐1, MAGE‐A and SSX proteins in esophageal cancer: Implications for immunotherapy A Akcakanat, T Kanda, T Tanabe, S Komukai, K Yajima, S Nakagawa, ... International journal of cancer 118 (1), 123-128, 2006 | 71 | 2006 |
| Rapamycin regulates the phosphorylation of rictor A Akcakanat, G Singh, MC Hung, F Meric-Bernstam Biochemical and biophysical research communications 362 (2), 330-333, 2007 | 69 | 2007 |
| Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors B Hassan, A Akcakanat, T Sangai, KW Evans, F Adkins, AK Eterovic, ... Oncotarget 5 (18), 8544, 2014 | 68 | 2014 |
